The impact of the rise in new drug rejections

May 17, 2017
Credit: CC0 Public Domain

The number of new drug applications rejected by the U.S. Food and Drug Administration has been on the rise. The cover story of Chemical & Engineering News (C&EN), the weekly newsmagazine of the American Chemical Society, explores why this is happening and what it means for patients.

Ann Thayer, a senior correspondent for C&EN, notes that in 2016, the FDA turned down 14 applications for novel drugs, more than the agency has rejected in recent years. Concurrent with this increase is a growing reliance on outside manufacturers. While outsourcing gives drug companies access to specialized manufacturing plants, it also opens them up to any problems those external firms might have. Often, drug rejections are due to these companies' failure to comply with .

Many drug companies and manufacturers eventually resolve the glitches and get their drugs approved. But the process can take a few months to a few years, which can leave patients with fewer treatment options while the snags get addressed. To help reduce delays, the FDA is providing guidance to for drawing up manufacturing-quality agreements with outside firms to help fix these problems before they have a chance to hold up applications.

Explore further: What to expect from big pharma in 2017

More information: "The complete response letter: The mail no one wants to receive," cen.acs.org/articles/95/i20/co … letter-mail-one.html

Related Stories

What to expect from big pharma in 2017

February 1, 2017

Last year, the Food and Drug Administration approved just 22 new therapeutic drugs, which is less than half the number approved in 2015. The cover story in Chemical & Engineering News (C&EN), the weekly newsmagazine of the ...

Pace of new drug approvals rise—and so do their price tags

February 3, 2016

Last year, more new drugs reached the market than in any year since 1996. But many have six-figure price tags for a year's worth of treatment and deliver only incremental health benefits. What does this mean for patients ...

Controversial drug approval stirs deep concerns—and hope

November 16, 2016

In September, the Food and Drug Administration approved Exondys, a controversial treatment for Duchenne muscular dystrophy based on tenuous data from just 12 patients. The cover story in Chemical & Engineering News (C&EN), ...

Reducing gene-damaging impurities in medicines

September 29, 2010

Drug manufacturers have been adjusting to strict new government standards that limit the amount of potentially harmful impurities in medicine, according to the cover story of the current issue of Chemical & Engineering News ...

Recommended for you

Key to expanding genetic code described

October 17, 2017

Yale scientists have described the atomic structure of a protein that is the key tool in efforts by synthetic biologists to expand the genetic code.

A new way to harness wasted methane

October 17, 2017

Methane gas, a vast natural resource, is often disposed of through burning, but new research by scientists at MIT could make it easier to capture this gas for use as fuel or a chemical feedstock.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.